Lupus low disease activity (SLE) in patients treated with belimumab: a single-center real-life experience (2016-2019).
Morton Aaron ScheinbergAndrea Pimentel GolmiaRicardo Prado GolmiaRoberta Nunes de Souza MolotievschiAline Pinheiro Dos Santos CortadaPublished in: Clinical rheumatology (2020)
Using the LLDAS, it was possible to show that the majority of patients receiving belimumab for prolonged periods go into remission steroid-free or in low disease activity in association with the corresponding immunosuppressive treatment. Key Points • Prolonged real-life evaluation confirms the efficacy and steroid-sparing of Belimumab in SLE patients with active disease.